title: Review of sentinel lymph node biopsy and systemic interferon for melanoma: promising but investigational modalities.
abstract: BACKGROUND
  There is conflicting data regarding the efficacy of systemic interferon as adjuvant therapy for high-risk cutaneous melanoma. Sentinel lymph node biopsy has recently gained acceptance in the surgical management of high-risk melanoma, despite a lack of data supporting its efficacy.
  
  
  OBJECTIVE
  To review the evidence concerning interferon and lymph node biopsy in the management of melanoma.
  
  
  METHODS
  A systematic review of all randomized, controlled trials involving adjuvant interferon and sentinel lymph node biopsy in management of melanoma is presented.
  
  
  RESULTS
  Current data regarding the efficacy of adjuvant interferon in the management of melanoma is conflicting. The conflicting results of studies involving both low-dose and high-dose systemic interferon for the adjuvant treatment of melanoma remain unresolved. There is no randomized, controlled data to support the use of sentinel lymph node biopsy in the management of melanoma, despite its widespread acceptance.
  
  
  CONCLUSIONS
  Sentinel lymph node biopsy and systemic interferon remain promising modalities in the management of melanoma, although there is no affinitive evidence to support their efficacy.
authors.affiliation: Department of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: C C
authors.initials: CC
authors.lastname: Otley
authors.forename: J A
authors.initials: JA
authors.lastname: Zitelli
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001706:Biopsy; D017024:Chemotherapy, Adjuvant; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000556:secondary*; D011994:Recombinant Proteins; D012307:Risk Factors; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins